ECSP19048402A - Compuestos de ácido ascórbico y quinona para el tratamiento de la enfermedad de chagas - Google Patents

Compuestos de ácido ascórbico y quinona para el tratamiento de la enfermedad de chagas

Info

Publication number
ECSP19048402A
ECSP19048402A ECSENADI201948402A ECDI201948402A ECSP19048402A EC SP19048402 A ECSP19048402 A EC SP19048402A EC SENADI201948402 A ECSENADI201948402 A EC SENADI201948402A EC DI201948402 A ECDI201948402 A EC DI201948402A EC SP19048402 A ECSP19048402 A EC SP19048402A
Authority
EC
Ecuador
Prior art keywords
ascorbic acid
treatment
chagas disease
mixture
quinone compounds
Prior art date
Application number
ECSENADI201948402A
Other languages
English (en)
Inventor
Celso Vataru Nakamura
Valdecir Farias Ximenes
Vânia Desoti
Sueli De Oliveira Silva Lautenschlager
Original Assignee
Ic Medtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ic Medtech Corp filed Critical Ic Medtech Corp
Publication of ECSP19048402A publication Critical patent/ECSP19048402A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se proporciona un método para tratar, prevenir o aliviar uno o más síntomas de enfermedad de Chagas en un sujeto, que comprende administrarle al sujeto (i) ácido ascórbico, o un enantiómero simple, una mezcla de enantiómeros, o una mezcla de diastereómeros de este; o una sal, solvato o hidrato farmacéuticamente aceptable de este; y (ii) un compuesto de quinona, o un enantiómero simple, una mezcla de enantiómeros, o una mezcla de diastereómeros de este; o una sal, solvato, hidrato o profármaco farmacéuticamente aceptable de este.
ECSENADI201948402A 2016-12-06 2019-07-08 Compuestos de ácido ascórbico y quinona para el tratamiento de la enfermedad de chagas ECSP19048402A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662430758P 2016-12-06 2016-12-06

Publications (1)

Publication Number Publication Date
ECSP19048402A true ECSP19048402A (es) 2019-09-30

Family

ID=62491595

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201948402A ECSP19048402A (es) 2016-12-06 2019-07-08 Compuestos de ácido ascórbico y quinona para el tratamiento de la enfermedad de chagas

Country Status (9)

Country Link
US (2) US11998523B2 (es)
AR (1) AR110317A1 (es)
CL (1) CL2019001529A1 (es)
CO (1) CO2019007158A2 (es)
CR (1) CR20190323A (es)
EC (1) ECSP19048402A (es)
MX (2) MX2019006593A (es)
PE (1) PE20191745A1 (es)
WO (1) WO2018106623A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468414B1 (en) 2001-02-16 2002-10-22 Hydro-Quebec Method of purification of a redox mediator before electrolytic regeneration thereof
US7091241B2 (en) 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
CA2689717C (en) 2006-06-16 2016-10-18 Summa Health System Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
WO2009035908A1 (en) * 2007-09-11 2009-03-19 Wyeth Compositions and their use for the treatment of protozoal infections comprising metaflumi zone
WO2009063044A1 (en) 2007-11-16 2009-05-22 Pharmaq As Treatment of parasite diseases using vitamin k3
CN105232532A (zh) 2009-07-20 2016-01-13 萨马保健系统公司 维生素c和维生素k的组合及其用途
CA2805745C (en) 2010-07-19 2019-01-15 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
KR101926320B1 (ko) 2010-08-04 2018-12-06 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
AU2014205324A1 (en) 2013-01-11 2015-07-30 Mayo Foundation For Medical Education And Research Vitamins C and K for treating polycystic diseases
CA3101331C (en) 2018-06-06 2023-12-19 IC-MedTech Corp. Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease

Also Published As

Publication number Publication date
CR20190323A (es) 2019-11-11
BR112019011789A2 (pt) 2019-10-29
PE20191745A1 (es) 2019-12-12
AR110317A1 (es) 2019-03-20
WO2018106623A1 (en) 2018-06-14
MX2022008055A (es) 2022-07-27
US20190343794A1 (en) 2019-11-14
CL2019001529A1 (es) 2019-11-08
US20240398755A1 (en) 2024-12-05
CO2019007158A2 (es) 2019-10-09
MX2019006593A (es) 2019-09-13
US11998523B2 (en) 2024-06-04

Similar Documents

Publication Publication Date Title
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
ECSP22019360A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
SV2018005742A (es) Inhibidores de mcl-1 macrocíclicos para tratar el cáncer
MX2019000451A (es) Compuesto heterociclico utilizado como inhibidor de fgfr.
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX386826B (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
UY35400A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
CL2020001244A1 (es) Inhibidores de inmunoproteasoma.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
UY37569A (es) Inhibidores del inmunoproteasoma
MX2021003842A (es) Terapia combinada para el tratamiento del cancer.
UY35903A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer